Reach Us +441902928240
Development Of �second-generation� Forms Of FGF-1 For Therapeutic Application | 6660
ISSN: 2157-7633

Journal of Stem Cell Research & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Development of �second-generation� forms of FGF-1 for therapeutic application

International Conference on Regenerative & Functional Medicine

Michael Blaber

ScientificTracks Abstracts: J Stem Cell Res Ther

DOI: 10.4172/2157-7633.S1.005

Fibroblast growth factor-1 (FGF-1) is a candidate growth factor for the treatment of chronic diabetic ulcers and other ischemic diseases. However, the relatively low thermal stability of FGF-1 makes it a poor candidate as a pharmaceutical compound. Formulation with soluble heparin substantially increases the thermo stability of FGF-1; however, while this approach to stabilizing FGF-1 improves the aggregation, storage and reconstitution properties it adds a number of undesirable cost and safety issues associated with heparin. Mutations that either stabilize FGF-1 or eliminate buried reactive thiols improve the in vitro functional half-life, protease resistance, and mitogenic activity in the absence of heparin. Pharmacokinetic (PK) studies of such mutants identify an additional undesirable consequence of heparin additive in the formulation; namely, it increases the endocrine-like properties of IV bolus FGF-1, and therefore also increases the probability of mitogenic activity at a distance from the site of delivery. Mutant FGF-1 with a diminished heparin binding site shows that heparan sulfate proteoglycan (HSPG) is the major effectors of the peripheral compartment in the pharmacokinetics of FGF-1; consequently, mutations that can enhance HSPG affinity can increase the mean residence time. Mutant FGF-1 proteins that do not require heparin in their formulation can therefore provide a number of important benefits for human therapeutic application.

Michael Blaber received his Ph.D. in 1990 from the University of California at Irvine College of Medicine and was an NIH funded postdoctoral fellow at the Institute of Molecular Biology at the University of Oregon. He has published more than 100 peer-reviewed articles, reviews and book chapters in areas of protein chemistry and biophysics, and is a current or past editorial board member for seven notable journals.

Leave Your Message 24x7